Diabetes, obesity & metabolism

Tolerability, safety, and effects of oral danuglipron at different dose schedules in type 2 diabetes: A 12-week controlled study

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

The study evaluates the tolerability and safety of different dose-escalation schemes of the oral GLP-1 receptor agonist danuglipron.

  • Different dose-escalation schemes of danuglipron were assessed for safety.
  • The tolerability of danuglipron may vary with different dosing strategies.
  • Pharmacodynamic effects of danuglipron were observed during the evaluation.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Oct '18
Safety and effectiveness of LY3298176, a new drug targeting two hormone receptors, in people with type 2 diabetes: a controlled phase 2 trial
top 1% journal
cited by 714 papers
randomized controlled trial
Jun '23
Retatrutide, a drug targeting three hormone receptors, for people with type 2 diabetes in a controlled US clinical trial
top 1% journal
cited by 367 papers
randomized controlled trial
Jun '18
MEDI0382, a drug targeting appetite and blood sugar control, tested in overweight and obese type 2 diabetes patients in a controlled dose study
top 1% journal
cited by 281 papers
randomized controlled trial
Jun '23
Orforglipron, a new oral drug activating blood sugar control receptors: Early tests with increasing doses in people with type 2 diabetes
cited by 45 papers
randomized controlled trial
Jun '23
Effectiveness and safety of different oral doses of orforglipron in people with type 2 diabetes
top 1% journal
cited by 138 papers
randomized controlled trial
Apr '22
Tirzepatide compared to placebo or semaglutide on insulin production and sensitivity in adults with type 2 diabetes
top 1% journal
cited by 219 papers
randomized controlled trial

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
today7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
1 week ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
2 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
3 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
4 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
5 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
6 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
7 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
8 weeks ago7 studies
issue #38
Two-thirds of patients kept weight off after stopping GLP-1 drugs
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief